Thesis (M.D.)--University of Maryland, 1815. / Microform version available in the Readex Early American Imprints series.

Ovarian cancers often develop resistance mechanisms against the standard platinum and taxane chemotherapy, which indicates the need for novel therapeutics to improve patient outcome. In vitro assays were performed to assess the effects and mechanism of action of a novel peptide, GAP-107B8, on ovarian cancer cell viability. Xenograft models were used to determine GAP-107B8’s effects on tumour burden in immune-incompetent mice. GAP-107B8 significantly reduced cell viability in ovarian cancer cell lines, although no synergistic effects with carboplatin were observed. This reduction in cell viability was due in part to apoptosis and may involve mechanisms leading to decreased pAKT, but without any change in pPKC levels. In vivo, GAP-107B8 had no effect on ovarian tumour burden, but significantly reduced ascites volume. The findings suggest that GAP-107B8 can reduce some malignant characteristics of cancer cells in vitro and in vivo and should be evaluated further as a potential therapeutic for ovarian cancer.

Ng Shu Wing. / Bibliography: leaves 196-216 / Thesis (M.Ph.)--Chinese University of Hong Kong, 1985

by Chan, Ting Wah Victor. / Bibliography: leaves 131-149 / Thesis (M.Phil.) -- Chinese University of Hong Kong, 1983

Thesis (M. Ph.)--Chinese University of Hong Kong. / Bibliography: l. 73-82.

Ovarian cancers often develop resistance mechanisms against the standard platinum and taxane chemotherapy, which indicates the need for novel therapeutics to improve patient outcome. In vitro assays were performed to assess the effects and mechanism of action of a novel peptide, GAP-107B8, on ovarian cancer cell viability. Xenograft models were used to determine GAP-107B8’s effects on tumour burden in immune-incompetent mice. GAP-107B8 significantly reduced cell viability in ovarian cancer cell lines, although no synergistic effects with carboplatin were observed. This reduction in cell viability was due in part to apoptosis and may involve mechanisms leading to decreased pAKT, but without any change in pPKC levels. In vivo, GAP-107B8 had no effect on ovarian tumour burden, but significantly reduced ascites volume. The findings suggest that GAP-107B8 can reduce some malignant characteristics of cancer cells in vitro and in vivo and should be evaluated further as a potential therapeutic for ovarian cancer.

Thesis (M.S.)--University of Wisconsin--Madison, 1961. / Typescript. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 25-30).

Thesis--University of California, Berkeley, 1962. / "UC-4 Chemistry" -t.p. "TID-4500 (17th Ed.)" -t.p. Errata sheet at end. Includes bibliographical references (p. 255-263).

Thesis (doctoral)--University of Copenhagen. / Bibliography: p. 53-68.

Thesis (Ph. D.)--University of Wisconsin--Madison, 1959. / Typescript. Vita. Includes reprints of 2 articles from Cancer research: Utilization of host purines by transplanted tumors / J. Frank Henderson and G.A. LePage. Vol. 19, no. 1 (Jan. 1959), p. 67-71 -- Observations on the action of azaserine in mammalian tissues / J. Frank Henderson, G.A. LePage, and Forde A. McIver. Vol. 17, no. 6 (July 1957), p. 609-612. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.